ArticleCancers2026
Reduced Local Tumor Progression After Thermal Ablation During Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma.
Tasuku Nakabori, Kaori Mukai, Taku Miyanaga, Hiroki Takiyama, Keita Sekiya, Takumi Kinomoto, Takanori Masumoto, Jun Murata, Makiko Urabe, Yugo Kai and 4 more
Abstract read
In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Tasuku NakaboriDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.ORCID 0000-0002-9486-850X Kaori MukaiDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Taku MiyanagaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Hiroki TakiyamaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Keita SekiyaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Takumi KinomotoDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Takanori MasumotoDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Jun MurataDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.ORCID 0009-0003-5303-8600 Makiko UrabeDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.ORCID 0009-0009-8033-3158 Yugo KaiDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Ryoji TakadaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.ORCID 0000-0002-6568-8091 Toshitaka MorishimaCancer Control Center, Osaka International Cancer Institute, Osaka 541-8567, Japan.ORCID 0000-0002-0747-3287 Minoru ShigekawaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.ORCID 0009-0006-9295-3651 Kazuyoshi OhkawaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
ablationatezolizumab plus bevacizumabhepatocellular carcinomaimmunotherapylocal tumor progression
Identifiers
PMID42279381
PMCPMC13255955
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390